Clinical and pathophysiological aspects of sepsis by Linnér, Anna
 Centrum för infektionsmedicin 
Institutionen för medicin, Huddinge 
  
Clinical and pathophysiological 
aspects of sepsis  
AKADEMISK AVHANDLING 
som för avläggande av medicine doktorsexamen vid Karolinska Institutet 
offentligen försvaras i föreläsningssal 4X, Alfred Nobels Allé 8, Karolinska 
Universitetssjukhuset Huddinge 
 





Professor Anna Norrby-Teglund 
Karolinska Institutet 
Institutionen för medicin, Huddinge 
Centrum för Infektionsmedicin 
 
Bihandledare:  
PhD Linda Johansson 
Karolinska Institutet 
Institutionen för medicin, Huddinge 
Centrum för Infektionsmedicin  
 
Docent Carl-Johan Treutiger 
Karolinska Institutet 
Institutionen för medicin, Huddinge 




Professor Shiranee Sriskandan 
Imperial College London 
Department of Medicine 
Section of Infectious Diseases and Immunity 
Hammersmith Campus, London, UK 
  
Betygsnämnd: 
Docent Anna Nilsson  
Karolinska Institutet 
Institutionen för kvinnors och barns hälsa 
 
Docent Volkan Özenci  
Karolinska Institutet 
Institutionen för laboratoriemedicin 
 
Docent Uga Dumpis  
University of Latvia 
Department of Infection Control  
ABSTRACT 
Severe sepsis and septic shock represent challenging problems for the health care system. 
Despite adequate antibiotics and modern intensive care, severe sepsis is associated with a 
substantial mortality rate of around 30%, which rises even higher if exacerbated by septic 
shock, and the incidence continues to increase. In severe sepsis and septic shock, the normally 
tightly controlled balance between the inflammatory, coagulatory and neuroendocrine systems 
is lost. Our understanding of the causes, mitigating factors and mediators of severe sepsis has 
advanced in the last number of years. However, immunomodulatory interventions specifically 
directed against cytokines that all appeared promising in animal studies, did not translate well 
into human clinical trials. It has been suggested that the failure of many sepsis trials may in part 
be due to enrollment of diverse patients with sepsis of varying severity and different causative 
microorganisms. We, and others, believe that successful clinical trials of immunotherapeutic 
agents in sepsis require well defined patient cohorts with respect to severity and microbiological 
aetiology. This thesis project aimed to document clinical presentation and outcome of severe 
sepsis and septic shock, to evaluate clinical efficacy of adjunctive polyspecific intravenous 
immunoglobulin therapy (IVIG) in streptococcal toxic shock syndrome (STSS) and to define 
pathogenic mechanisms in sepsis, with a specific emphasis on the role of heparin-binding 
protein (HBP) and resistin; recently identified markers of severity in sepsis.  
In paper I we conducted a prospective observational study of 101 patients with severe sepsis 
and septic shock. We reported a relatively low mortality in severe sepsis/septic shock, in 
aspects of both short- and long-term mortality, compared to studies outside Scandinavia. A 
troubling finding was that women received delayed antibiotics as compared to men.  
In paper II, we documented clinical efficacy of IVIG therapy in a comparative observational 
study of 67 patients with STSS. This study demonstrated a significantly reduced mortality rate 
among STSS patients receiving IVIG as compared to patients who did not. Also clindamycin 
therapy was identified as an important factor for survival. The IVIG-group had a higher 
degree of NF as compared to the non-IVIG group. 
In paper III and IV, the role of novel biomarkers in sepsis, i.e. HBP and resistin was explored 
in vitro and in vivo. Paper III focuses on resistin responses in STSS and necrotizing fasciitis 
(NF). The results demonstrate that STSS and NF are characterized by hyperresistinemia in 
circulation as well as at the local site of infection. Importantly, neutrophils were identified as 
a novel and dominant source of resistin in bacterial septic shock. In vitro assays using primary 
neutrophils showed that resistin release was readily triggered by streptococcal cell wall 
components and by the streptococcal M1 protein, but not by the potent streptococcal 
superantigens or LPS. In paper IV we explored whether neutrophil responses, in particular the 
release of sepsis-associated factors HBP and resistin, vary depending on bacterial stimuli and 
how this relates to sepsis of different aetiology. Fixed streptococcal strains induced significantly 
higher release of HBP and resistin, compared to S. aureus or E. coli. In vivo analyses of HBP 
and resistin in plasma of septic patients revealed elevated levels as compared to non-infected 
critically ill patients. HBP and resistin correlated significantly in septic patients, with the 
strongest association seen in group A streptococcal cases. The study reveals pronounced 
differences in neutrophil responses to various bacterial stimuli, and shows that streptococcal 
strains are particularly potent inducers of HBP and resistin. 
 
In summary, this thesis provides new insight concerning mortality of sepsis patients in intensive 
care units and further supports the adjunctive treatment with IVIG in STSS patients. It also adds 
to the understanding of the complex pathophysiology of sepsis and our observations on bacterial 
induced neutrophil activation underscore the need for personalized medicine in sepsis. 
